Education
About Us
Working with TipRanks
Follow Us
Kaleido Biosciences Inc (KLDO)
OTHER OTC:KLDO
Total Valuation
Kaleido Biosciences has a market cap or net worth of $4.26K. The enterprise value is -$16.78M.
Market Cap$4.26K
Enterprise Value-$16.78M
Share Statistics
Kaleido Biosciences has 42,622,560 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding42,622,560
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Kaleido Biosciences’s return on equity (ROE) is -8.51 and return on invested capital (ROIC) is -239.53%.
Return on Equity (ROE)-8.51
Return on Assets (ROA)-1.80
Return on Invested Capital (ROIC)-239.53%
Return on Capital Employed (ROCE)-4.29
Revenue Per Employee14.53K
Profits Per Employee-1.19M
Employee Count76
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kaleido Biosciences is ―. Kaleido Biosciences’s PEG ratio is 0.10.
PE Ratio―
PS Ratio90.62
PB Ratio9.43
Price to Fair Value9.43
Price to FCF-1.28
Price to Operating Cash Flow>-0.01
PEG Ratio0.10
Income Statement
In the last 12 months, Kaleido Biosciences had revenue of 1.10M and earned -90.29M in profits. Earnings per share was -2.16.
Revenue1.10M
Gross Profit-1.25M
Operating Income-87.67M
Pretax Income-90.29M
Net Income-90.29M
EBITDA-85.09M
Earnings Per Share (EPS)-2.16
Cash Flow
In the last 12 months, operating cash flow was -77.09M and capital expenditures -1.13M, giving a free cash flow of -78.22M billion.
Operating Cash Flow-77.09M
Free Cash Flow-78.22M
Free Cash Flow per Share-1.84
Dividends & Yields
Kaleido Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta401.57
52-Week Price Change400.00%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)385.00
Important Dates
Kaleido Biosciences upcoming earnings date is Nov 7, 2022, TBA (Confirmed).
Last Earnings DateAug 10, 2022
Next Earnings DateNov 7, 2022
Ex-Dividend Date―
Financial Position
Kaleido Biosciences as a current ratio of 1.43, with Debt / Equity ratio of 204.53%
Current Ratio1.43
Quick Ratio1.43
Debt to Market Cap0.22
Net Debt to EBITDA0.20
Interest Coverage Ratio-30.89
Taxes
In the past 12 months, Kaleido Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Kaleido Biosciences EV to EBITDA ratio is -0.98, with an EV/FCF ratio of -1.06.
EV to Sales75.42
EV to EBITDA-0.98
EV to Free Cash Flow-1.06
EV to Operating Cash Flow-1.08
Balance Sheet
Kaleido Biosciences has $38.47M in cash and marketable securities with $21.69M in debt, giving a net cash position of $16.78M billion.
Cash & Marketable Securities$38.47M
Total Debt$21.69M
Net Cash$16.78M
Net Cash Per Share$0.39
Tangible Book Value Per Share$0.25
Margins
Gross margin is -113.59%, with operating margin of -7940.85%, and net profit margin of -8178.26%.
Gross Margin-113.59%
Operating Margin-7940.85%
Pretax Margin-8178.26%
Net Profit Margin-8178.26%
EBITDA Margin-7707.61%
EBIT Margin-7921.20%
Analyst Forecast
The average price target for Kaleido Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―